Welcome to CDC Stacks | The 25th anniversary of the discovery of the Hepatitis C virus : looking back to look forward - 23536 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
The 25th anniversary of the discovery of the Hepatitis C virus : looking back to look forward
  • Published Date:
    June 17, 2014
  • Source:
    Public health grand rounds ; 2014 June 17
  • Language:
    English
Filetype[PDF - 2.51 MB]


Details:
  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Office of the Associate Director for Communication. ; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Viral Hepatitis. ;
  • Document Type:
  • Description:
    The Epidemiology of Hepatitis C: how did we get here? [PDF version of the PowerPoint presentation by John W. Ward, p. 2-21] -- Hepatitis C: the curative era [PDF version of the PowerPoint presentation by David Thomas, p. 22-38] -- Steps toward ending Hepatitis C in the U.S. [PDF version of the PowerPoint presentation by Phillip O. Coffin, p. 39-56].

    Twenty-five years ago CDC played a pivotal role in the discovery of the virus that causes hepatitis C. After the isolation of HCV, implementation of screening of blood products and organs for donation led to a decrease in rates of HCV infection between 1990 and 2009. In spite of these successes, HCV still remains a serious threat, both domestically and abroad. HCV remains the most common chronic blood borne infection in the United States, affecting approximately 3.9 million individuals. However up to 50% of HCV-infected persons are unaware of their infection. Globally, there are 180 million people who are chronically infected with the virus, and 3-4 million new infections occur every year.

    Recent therapeutic advances hold the potential to halt the progression of HCV infection and disease. While HCV-infected persons can be effectively treated, more effort is needed to screen, diagnosis, treat and provide continuity of care. This session of Public Health Grand Rounds will discuss how new screening guidelines, testing methods and therapeutic advances will provide us with an opportunity to improve individual outcomes and to eventually eliminate HCV infection.

    Presented by: John W. Ward, MD
, Director, Division of Viral Hepatitis
, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC
 [“The Epidemiology of Hepatitis C: How Did We Get Here?"]; David Thomas, MD, MPH
, Stanhope Bayne Jones Professor of Medicine, 
Chief of Infectious Diseases, Johns Hopkins School of Medicine
 [“Hepatitis C: The Curative Era”]; Phillip O. Coffin, MD, MIA, 
Director of Substance Use Research, 
San Francisco Department of Public Health, University of California San Francisco
 [“Steps toward Ending Hepatitis C in the U.S.”].

    Facilitated by: John Iskander, MD, MPH, Scientific Director, Public Health Grand Rounds; 
Phoebe Thorpe, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds; 
Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds.

  • Supporting Files:
    No Additional Files